Jones RS, Smith PS, Berg PH, de la Peña A, Cook PP, Shawa I, Kioussopoulos KM, Hu Y, Schott RJ. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19.
CLINICAL MEDICINE INSIGHTS: CIRCULATORY, RESPIRATORY AND PULMONARY MEDICINE 2022;
16:11795484221119316. [PMID:
35991210 PMCID:
PMC9382233 DOI:
10.1177/11795484221119316]
[Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 07/20/2022] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND
Severe cases of coronavirus disease 2019 (COVID-19) are characterized by
progressive respiratory failure and the development of acute respiratory
distress syndrome (ARDS), with high mortality rates for patients requiring
mechanical ventilation. Levels of the vascular growth factor Angiopoietin 2
(Ang2) in plasma have been strongly correlated with increased ARDS risk in
patients with pneumonia or sepsis. The intent of this study was to determine
whether LY3127804, an anti-Ang2 monoclonal antibody, could reduce the need
for mechanical ventilation among patients admitted to the hospital with
pneumonia and presumed or confirmed COVID-19.
METHODS
Patients admitted to hospital with confirmed pneumonia, presumed or confirmed
COVID-19, and infiltrates on chest imaging and/or oxygen saturation of ≤ 95%
on room air were stratified by age group (< 65 years and ≥ 65 years),
sex, and site and randomly assigned 1:1 within each stratum to receive
either LY3127804 (20 mg/kg) or placebo on Day 1 and possibly on Day 15. The
primary end point for this study was number of days in which a patient did
not require a ventilator over the 28-day study period.
RESULTS
Interim analysis assessed study futility after 95 randomized patients had
28-day data available and showed no benefit of LY3127804 in reducing the
number of ventilator days over placebo. The study was subsequently
terminated.
CONCLUSION
LY3127804 treatment did not decrease the need for ventilator usage in
patients hospitalized with pneumonia and presumed or confirmed COVID-19.
ClinicalTrials.gov identifier
NCT04342897
Collapse